Phophorylated Akt protein expression in non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 10, Issue 5, 2007, Pages 376-380

  Zhou, Zuli ^a   Yang, Fan ^b   Jiang, Guan Chao ^b   Huang, Yuqing ^b   Fu, Jing ^b   Wang, Jun ^b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b NONE

Author keywords

Epidermal growth factor receptor; Non small cell lung cancer; Phosphorylated Akt; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE B;

AGE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME PHOSPHORYLATION; FEMALE; GENDER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; MALE; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; SMOKING; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR DIFFERENTIATION;

EID: 35948957416     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin,2006,56(2) : 106-130.
2. Ettinger DS. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer. Oncologist,2006,11(4) : 358-373.
3. Balsara BR, Pei J, Mitsuuchi Y, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis,2004,25(11) : 2053-2059.
4. Crowell JA, Steele VE. AKT and the phosphatidylinositol 3-kinase/AKT pathway: important molecular targets for lung cancer prevention and treatment. J Natl Cancer Inst,2003,95(4) : 252-253.
5. Comment on: J Natl Cancer Inst,2003,95(4) : 291-302.
6. Cappuzzo F, Magrini E, Ceresoli GL, et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst,2004,96(15) : 1133-1141.
7. Comment in: J Natl Cancer Inst,2004,96(15) : 1117-1119;
8. J Natl Cancer Inst,2004,96(23) : 1795; author reply 1795-1796;
9. J Natl Cancer Inst,2005,97(6) : 461-462; author reply 462-463.
10. Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer,2005,113(1) : 109-115.
11. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol, 2003, 21 (20) : 3798-3807.
12. Comment in; J Clin Oncol,2003,21(23) : 4268-4269;
13. J Clin Oncol,2004,22(17) : 3646; author reply 3646-3648.
14. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science,2004, 305(5687) : 1163-1167.
15. Cantley LC. The phosphoinositide 3-kinase pathway. Science, 2002,296(5573) : 1655-1657.
16. Mukohara T, Kudoh S, Yamauchi S, et al. Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer,2003,41(2) : 123-130.
17. Suzuki S, Igarashi S, Hanawa M, et al. Diversity of epidermal growth factor receptor-mediated activation of downstream molecules in human lung carcinomas. Mod Pathol,2006,19(7) : 986-998.
18. David O, Jett J, LeBeau H, et al. Phospho-Akt overexpression in non-small cell lung cancer confers significant stage-independent survival disadvantage. Clin Cancer Res,2004,10(20) : 6865-6871.
19. Hirami Y, Aoe M, Tsukuda K, et al. Relation of epidermal growth factor receptor, phosphorylated-Akt, and hypoxia-inducible factor-lalpha in non-small cell lung cancers. Cancer Lett, 2004,214(2) : 157-164.
20. Tsao AS, McDonnell T, Lam S, et al. Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev, 2003,12(7) : 660-664.
21. Tang JM, He QY, Guo RX, et al. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer,2006,51(2) : 181-191.
22. Shah A, Swain WA, Richardson D, et al. Phospho-akt expression is associated with a favorable outcome in non-small cell lung cancer. Clin Cancer Res,2005,11(8) : 2930-2936.